LGM
XLRN

Logos Global Management’s Acceleron Pharma XLRN Stock Holding History

Logos Global Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-267,676
Closed -$14.2M – 58
2019
Q4 		$14.2M Buy
+267,676
New +$12.2M 3.5% 12

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Logos Global Management's XLRN Position: Q1 2020 in Review

Logos Global Management sold out of Acceleron Pharma (XLRN) in Q1 2020, closing a stake of 267,676 shares — an estimated $14.2M sold.

Logos Global Management first reported a position in XLRN in Q4 2019 and held it in 1 quarter. The position peaked at $14.2M in Q4 2019. 217 funds tracked by Wall St. Rank hold XLRN as of Q1 2020.

  • Logos Global Management reported no remaining Acceleron Pharma position as of Q1 2020 after selling out during the quarter.
  • Logos Global Management sold 267,676 Acceleron Pharma shares in Q1 2020, an estimated $14.2M.
  • Logos Global Management first reported a position in Acceleron Pharma in Q4 2019 and held it in 1 quarter.
  • Logos Global Management's Acceleron Pharma position peaked at $14.2M in Q4 2019.
  • 217 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2020.

Based on Logos Global Management's 13F filing for Q1 2020, filed 15 May 2020.